Tamoxifen [10540-29-1]

Katalog-Nummer HY-13757A-5g

Size : 5g

Marke : MedChemExpress

Weitere Informationen anfordern

Contact local distributor :


Telefonnummer : +1 850 650 7790

Beschreibung

Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[1][2][3]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[5]. Tamoxifen activates autophagy and induces apoptosis[4]. Tamoxifen also can induce gene knockout of CreER transgenic mouse[6].

IC50 & Target[1][4]

Estrogen receptor

 

HSP90

 

Cellular Effect
Cell Line Type Value Description References
518A2 IC50
7.62 μM
Compound: 2
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 22749392]
A2058 EC50
12.5 μM
Compound: TAM
Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
[PMID: 31099568]
A253 cell line IC50
8.92 μM
Compound: 2
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
[PMID: 22749392]
A2780 GI50
30.3 μM
Compound: 1
Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay
[PMID: 27128175]
A2780 IC50
7.77 μM
Compound: 2
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 22749392]
A-431 IC50
> 100 μM
Compound: Tamoxifen
Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
[PMID: 29605808]
A549 IC50
1.86 μg/mL
Compound: Tomoxifen
Cytotoxicity against human A549 cells by alamar blue assay
Cytotoxicity against human A549 cells by alamar blue assay
[PMID: 11720540]
A549 IC50
10.08 μM
Compound: Tamoxifen
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
[PMID: 31884407]
A549 IC50
10.87 μM
Compound: Tamoxifen
Antiproliferative activity against human A549 cells by MTT assay
Antiproliferative activity against human A549 cells by MTT assay
[PMID: 31546197]
A549 IC50
12 μM
Compound: TAM
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
[PMID: 23287057]
A549 IC50
17.3 μM
Compound: Tamoxifen
Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
[PMID: 29605808]
A549 IC50
17.3 μM
Compound: Tamoxifen
Anticancer activity against human A549 cells measured after 48 hrs by SRB assay
Anticancer activity against human A549 cells measured after 48 hrs by SRB assay
[PMID: 27671497]
A549 GI50
24.4 μM
Compound: Tamoxifen
Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
[PMID: 26163220]
A549 IC50
8.4 μM
Compound: Tamoxifen
Cytotoxicity against human A549 cells assessed as cell viability by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability by MTT assay
[PMID: 26079090]
A549 IC50
9.66 μM
Compound: 2
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 22749392]
Astrocyte IC50
> 10 μM
Compound: Tamoxifen
Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
[PMID: 26355532]
B16-F10 IC50
64.87 μM
Compound: Tam
Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay
Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay
[PMID: 25222876]
CHO IC50
> 100 μM
Compound: Tam
Antiproliferative activity against CHO cells after 2 days by MTT assay
Antiproliferative activity against CHO cells after 2 days by MTT assay
[PMID: 25222876]
DLD-1 IC50
11.06 μM
Compound: Tamoxifen
Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay
Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay
[PMID: 27671497]
DLD-1 IC50
16.3 μM
Compound: Tamoxifen
Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
[PMID: 29605808]
DLD-1 IC50
4.78 μM
Compound: 2
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
[PMID: 22749392]
DU-145 IC50
10.87 μM
Compound: Tamoxifen
Antiproliferative activity against human DU145 cells by MTT assay
Antiproliferative activity against human DU145 cells by MTT assay
[PMID: 31546197]
DU-145 IC50
18.07 μM
Compound: Tamoxifen
Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay
Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay
[PMID: 27671497]
DU-145 GI50
19.3 μM
Compound: Tamoxifen
Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
[PMID: 26163220]
DU-145 IC50
28.9 μM
Compound: Tamoxifen
Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 23786452]
DU-145 IC50
5.5 μM
Compound: TAM
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
[PMID: 23287057]
DU-145 GI50
6.07 μM
Compound: Tamoxifen
Anticancer activity against human DU145 cells after 24 hrs by SRB assay
Anticancer activity against human DU145 cells after 24 hrs by SRB assay
[PMID: 19733085]
EKVX GI50
6.3 μM
Compound: TAM
Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay
[PMID: 26896706]
FaDu IC50
5.39 μM
Compound: Tamoxifen
Anticancer activity against human FADU cells measured after 48 hrs by SRB assay
Anticancer activity against human FADU cells measured after 48 hrs by SRB assay
[PMID: 27671497]
Fibroblast IC50
> 20 μM
Compound: TAM
Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay
Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay
[PMID: 23287057]
Fibroblast CC50
11.1 μM
Compound: Tamoxifen
Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 33373820]
Fibroblast CC50
12.7 μM
Compound: Tamoxifen
Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
[PMID: 33373820]
HCT-116 IC50
45 μM
Compound: Tamoxifen
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
[PMID: 31884407]
HCT-15 GI50
3.16 μM
Compound: TAM
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay
[PMID: 26896706]
HEK293 IC50
> 50 μM
Compound: Tamoxifen
Cytotoxicity against HEK293 cells by MTT assay
Cytotoxicity against HEK293 cells by MTT assay
[PMID: 31546197]
HEK293 IC50
10 μM
Compound: Tamoxifen
Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
[PMID: 20605470]
HEK293 IC50
10 μM
Compound: Tamoxifen
Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
[PMID: 21871812]
HEK293 CC50
13 μg/mL
Compound: TAM
Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
[PMID: 30316060]
HEK293 CC50
13.1 μg/mL
Compound: Tamoxifen
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay
[PMID: 30901686]
HEK293 CC50
13.1 μg/mL
Compound: Tamoxifen
Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay
[PMID: 30831407]
HEK293 IC50
20.93 μM
Compound: Tamoxifen
Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
[PMID: 29054359]
HEK293 IC50
22.4 μM
Compound: TAM
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 34153643]
HEK293 IC50
24 μM
Compound: Tamoxifen
Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay
Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay
[PMID: 35477062]
HEK293 IC50
24 μM
Compound: Tamoxifen
Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
[PMID: 30975502]
HEK293 IC50
26 μM
Compound: TAM
Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
[PMID: 24457094]
HEK293 IC50
26.33 μM
Compound: 1
Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 35276362]
HEK293 CC50
39.4 μM
Compound: Tamoxifen
Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
[PMID: 30322754]
HEK293 IC50
50 μM
Compound: Tamoxifen
Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
[PMID: 24880230]
HEK293 CC50
62 μM
Compound: Tamoxifen
Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
[PMID: 28257200]
HEK293 CC50
9 μg/mL
Compound: Tamoxifen
Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay
Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay
[PMID: 33609657]
HEK293 CC50
9 μg/mL
Compound: Tamoxifen
Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
[PMID: 32619924]
HEK293 CC50
9 μg/mL
Compound: Tamoxifen
Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method
Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method
[PMID: 33738069]
HEK-293T IC50
0.039 μM
Compound: Tamoxifen
Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay
Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay
[PMID: 23786452]
HeLa IC50
0.341 μM
Compound: Tamoxifen
Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
[PMID: 28882502]
HeLa IC50
0.73 μM
Compound: Tamoxifen
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
[PMID: 29624387]
HeLa IC50
1.53 μM
Compound: Tamoxifen
Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
[PMID: 28882502]
HeLa IC50
10.87 μM
Compound: Tamoxifen
Antiproliferative activity against human HeLa cells by MTT assay
Antiproliferative activity against human HeLa cells by MTT assay
[PMID: 31546197]
HeLa GI50
12 μM
Compound: 1
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
[PMID: 27128175]
HeLa IC50
12.5 μM
Compound: Tamoxifen
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
[PMID: 20605470]
HeLa GI50
32.6 μM
Compound: 1
Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay
Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay
[PMID: 23735829]
HeLa IC50
8.85 μM
Compound: Tamoxifen
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 28838694]
Hepatocyte EC50
34.4 μM
Compound: Tamoxifen
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay
[PMID: 22531045]
Hepatocyte EC50
67.6 μM
Compound: Tamoxifen
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay
[PMID: 22531045]
Hepatocyte EC50
71.4 μM
Compound: Tamoxifen
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay
[PMID: 22531045]
HepG2 IC50
12 μM
Compound: Tamoxifen
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
[PMID: 30613327]
HepG2 IC50
19.6 μM
Compound: Tamoxifen
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay
[PMID: 34015704]
HepG2 GI50
21.7 μM
Compound: Tamoxifen
Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
[PMID: 26163220]
HepG2 IC50
23.4 μM
Compound: tamoxifen
Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay
Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay
[PMID: 20545334]
HepG2 CC50
24.7 μM
Compound: Tamoxifen
Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis
Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis
[PMID: 30322754]
HepG2 EC50
35 μM
Compound: Tamoxifen
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay
[PMID: 27652492]
HepG2 EC50
35 μM
Compound: Tamoxifen
Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay
Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay
[PMID: 27652492]
HepG2 IC50
6.3 μM
Compound: TAM
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
[PMID: 23287057]
HepG2 CC50
62 μM
Compound: Tamoxifen
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
[PMID: 28257200]
HL-60 IC50
14.3 μM
Compound: Tamoxifen
Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS
Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS
[PMID: 22901895]
HL-60 IC50
5.9 μg/mL
Compound: 1, Tamoxifen
Growth inhibition of human HL60 cells after 4 hrs by MTT assay
Growth inhibition of human HL60 cells after 4 hrs by MTT assay
[PMID: 17904372]
HT-29 IC50
1.86 μg/mL
Compound: Tomoxifen
Cytotoxicity against human HT-29 cells by alamar blue assay
Cytotoxicity against human HT-29 cells by alamar blue assay
[PMID: 11720540]
HT-29 IC50
38.6 μM
Compound: tamoxifen
Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay
Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay
[PMID: 20545334]
Ishikawa IC50
0.42 μM
Compound: tamoxifen
Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA
Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA
[PMID: 9784163]
Ishikawa IC50
14.58 μM
Compound: Tamoxifen
Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
[PMID: 34509864]
Ishikawa IC50
16.47 μM
Compound: Tamoxifen
Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
[PMID: 28460819]
Ishikawa IC50
16.78 μM
Compound: Tamoxifen
Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
[PMID: 34022716]
Ishikawa IC50
170 nM
Compound: 1a
Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs
Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs
[PMID: 18835176]
Ishikawa IC50
20.65 μM
Compound: Tamoxifen
Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
[PMID: 28942113]
Ishikawa IC50
22.5 μM
Compound: Tamoxifen
Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay
Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay
[PMID: 21871812]
Ishikawa IC50
26.52 μM
Compound: Tamoxifen
Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
[PMID: 29587221]
Ishikawa IC50
6 μM
Compound: Tamoxifen
Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay
[PMID: 27176944]
Ishikawa IC50
7.87 μg/mL
Compound: Tamoxifen
Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay
[PMID: 28442256]
J774.A1 CC50
11.06 μM
Compound: Tamoxifen
Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay
Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay
[PMID: 31376569]
Jurkat IC50
8.3 μM
Compound: Tamoxifen
Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay
Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay
[PMID: 23792352]
K562 GI50
5.2 μM
Compound: tamoxifen
Antiproliferative activity against human K562 cells after 72 hrs
Antiproliferative activity against human K562 cells after 72 hrs
[PMID: 25420175]
MCF-10A IC50
> 1000 μM
Compound: Tamoxifen
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
[PMID: 36603398]
MCF-10A IC50
> 1000 μM
Compound: Tamoxifen
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
[PMID: 36603398]
MCF-10A IC50
> 50 μM
Compound: Tamoxifen
Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay
Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay
[PMID: 33340662]
MCF7 IC50
< 1000 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
[PMID: 36603398]
MCF7 EC50
> 200 nM
Compound: 2
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
[PMID: 34251202]
MCF7 IC50
0.027 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
[PMID: 22472045]
MCF7 IC50
0.794 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells after 5 days
Cytotoxicity against human MCF7 cells after 5 days
[PMID: 23864928]
MCF7 IC50
1 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells by MTT assay
Antiproliferative activity against human MCF7 cells by MTT assay
[PMID: 20451380]
MCF7 IC50
1.31 μg/mL
Compound: Tamoxifen
Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay
Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay
[PMID: 31884407]
MCF7 GI50
1.58 μM
Compound: TAM
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
[PMID: 26896706]
MCF7 IC50
1.82 μM
Compound: TAMOX, TAM
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
[PMID: 23123017]
MCF7 IC50
1.89 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 24721727]
MCF7 EC50
10 nM
Compound: 3 (Tamoxifen)
Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.
Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.
[PMID: 12825935]
MCF7 IC50
10 μM
Compound: tamoxifene
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
[PMID: 19423356]
MCF7 IC50
10.74 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay
Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay
[PMID: 37146520]
MCF7 IC50
10.87 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells by MTT assay
Antiproliferative activity against human MCF7 cells by MTT assay
[PMID: 31546197]
MCF7 IC50
10.9 μM
Compound: Tamoxifen
Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay
Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay
[PMID: 19836230]
MCF7 IC50
11 μM
Compound: Tamoxifen
Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay
Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay
[PMID: 12565971]
MCF7 IC50
11.1 μM
Compound: Tamoxifen
Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
[PMID: 19836230]
MCF7 IC50
11.35 μM
Compound: Tamoxifen
Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay
[PMID: 28460819]
MCF7 IC50
11.4 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells by WST-1 assay
Cytotoxicity against human MCF7 cells by WST-1 assay
[PMID: 19836230]
MCF7 IC50
11.44 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 23022281]
MCF7 IC50
11.55 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
[PMID: 31884407]
MCF7 IC50
11.8 μM
Compound: Tamoxifen
Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay
Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay
[PMID: 20951035]
MCF7 IC50
12 μM
Compound: tamoxifen
Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay
Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay
[PMID: 19446930]
MCF7 GI50
12 μM
Compound: 1
Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay
Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay
[PMID: 23735829]
MCF7 IC50
12.35 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 23830503]
MCF7 IC50
12.48 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
[PMID: 21871812]
MCF7 IC50
12.5 μM
Compound: Tam
Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay
10.1039/C4MD00289J
MCF7 IC50
13.45 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 23902804]
MCF7 IC50
13.7 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells by MTT reduction assay
Antiproliferative activity against human MCF7 cells by MTT reduction assay
[PMID: 33421712]
MCF7 IC50
14.35 μM
Compound: Tamoxifen
Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
[PMID: 28942113]
MCF7 IC50
15.2 μM
Compound: 6
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 23880359]
MCF7 IC50
15.21 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 33340662]
MCF7 IC50
15.46 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 29587221]
MCF7 IC50
15.6 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 23786452]
MCF7 IC50
16.7 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 30384047]
MCF7 IC50
18.18 μM
Compound: Tamoxifen
Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay
Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay
[PMID: 27671497]
MCF7 IC50
18.71 μM
Compound: tamoxifen
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay
[PMID: 25734623]
MCF7 IC50
19.2 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay
[PMID: 33852304]
MCF7 IC50
19.33 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay
[PMID: 27311894]
MCF7 IC50
19.5 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 29482944]
MCF7 IC50
19.54 μM
Compound: Tam
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
[PMID: 22647217]
MCF7 IC50
2.1 μM
Compound: tamoxifen
Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay
Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay
[PMID: 25614118]
MCF7 IC50
20 nM
Compound: 7
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
[PMID: 33479633]
MCF7 IC50
200 nM
Compound: Tamoxifen
Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method
Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method
[PMID: 23448346]
MCF7 IC50
21.57 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
[PMID: 28505536]
MCF7 IC50
22.6 μM
Compound: TAM
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
[PMID: 31620225]
MCF7 IC50
25 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
[PMID: 31673312]
MCF7 IC50
25 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method
Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method
[PMID: 31610378]
MCF7 IC50
27.96 μM
Compound: 1, TAM
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 23860592]
MCF7 IC50
3.8 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay
[PMID: 26079090]
MCF7 IC50
3.99 μg/mL
Compound: Tamoxifen
Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay
[PMID: 28442256]
MCF7 IC50
30 nM
Compound: Tam
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
[PMID: 33257172]
MCF7 IC50
31 μM
Compound: TEM
Cytotoxicity activity against human MCF7 cells by MTS assay
Cytotoxicity activity against human MCF7 cells by MTS assay
[PMID: 21680064]
MCF7 IC50
4 μM
Compound: TAM
Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay
Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay
[PMID: 31129455]
MCF7 IC50
4.1 μM
Compound: 2a
Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay
[PMID: 28426931]
MCF7 IC50
4.1 μM
Compound: 2
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 25369367]
MCF7 IC50
4.1 μM
Compound: Tamoxifen
Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay
Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay
[PMID: 27407030]
MCF7 IC50
4.12 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
[PMID: 31987694]
MCF7 IC50
4.12 μM
Compound: 1a
Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay
[PMID: 18835176]
MCF7 IC50
4.4 μM
Compound: TAM
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 26896706]
MCF7 IC50
4.4 μM
Compound: 2a
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay
[PMID: 28426931]
MCF7 IC50
4.67 μM
Compound: Tam
Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay
Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay
[PMID: 25222876]
MCF7 IC50
42.4 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
[PMID: 30731397]
MCF7 ED50
5 μg/mL
Compound: TAM
Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay
[PMID: 19425534]
MCF7 IC50
5.09 μM
Compound: TAM
Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs
Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs
[PMID: 16979337]
MCF7 IC50
5.19 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
[PMID: 23806014]
MCF7 IC50
5.3 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
[PMID: 27176944]
MCF7 IC50
5.3 μM
Compound: Tamoxifen
Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
[PMID: 29220789]
MCF7 IC50
5.4 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
[PMID: 34726897]
MCF7 IC50
5.5 μM
Compound: TAM
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 23287057]
MCF7 IC50
5.62 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
[PMID: 33894490]
MCF7 IC50
50 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay
[PMID: 36846377]
MCF7 IC50
50 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
[PMID: 36846377]
MCF7 IC50
50 μM
Compound: Tamoxifen
Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 26972118]
MCF7 IC50
54 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
[PMID: 33234343]
MCF7 IC50
55.5 μM
Compound: Tamoxifen
Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
10.1007/s00044-012-0391-5
MCF7 IC50
580 nM
Compound: tamoxifen
Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay
[PMID: 18272256]
MCF7 IC50
580 nM
Compound: 3 (Tamoxifen)
Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay.
Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay.
[PMID: 12825935]
MCF7 IC50
6 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
[PMID: 24880230]
MCF7 IC50
6.3 μM
Compound: Tamoxifen
Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
[PMID: 33373820]
MCF7 GI50
6.5 μM
Compound: 1
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
[PMID: 27128175]
MCF7 GI50
6.8 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay
[PMID: 28152429]
MCF7 IC50
6.99 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells by resazurin microplate assay
Cytotoxicity against human MCF7 cells by resazurin microplate assay
[PMID: 27228159]
MCF7 IC50
64.3 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
[PMID: 25164760]
MCF7 IC50
7.09 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
[PMID: 30360952]
MCF7 IC50
7.1 μM
Compound: 2
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 22749392]
MCF7 IC50
7.65 μM
Compound: TAM
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 19740667]
MCF7 IC50
7.94 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay
Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay
[PMID: 28927795]
MCF7 IC50
8 μg/mL
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
[PMID: 24576797]
MCF7 GI50
8 μM
Compound: Tamoxifen
Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay
[PMID: 26163220]
MCF7 IC50
8.12 μM
Compound: Tamoxifen
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 29054359]
MCF7 IC50
8.31 μg/mL
Compound: TAM
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
[PMID: 21115211]
MCF7 IC50
8.38 μg/mL
Compound: Tamoxifen
Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay
[PMID: 32771798]
MCF7 IC50
8.42 μM
Compound: TAM
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 34153643]
MCF7 IC50
8.5 μg/mL
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
[PMID: 36325400]
MCF7 IC50
8.53 μM
Compound: 1
Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 35276362]
MCF7 IC50
8.6 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS
Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS
[PMID: 22901895]
MCF7 IC50
8.61 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
[PMID: 29605808]
MCF7 IC50
8.9 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
[PMID: 20605470]
MCF7 IC50
82.5 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 25164760]
MCF7 IC50
9 μM
Compound: Tamoxifen
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
[PMID: 32731188]
MCF7 IC50
9 μM
Compound: TAM
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
[PMID: 24457094]
MCF7 IC50
9.6 μM
Compound: Tamoxifen
Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 33373820]
MDA-MB-231 IC50
< 1000 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
[PMID: 36603398]
MDA-MB-231 IC50
> 20 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
[PMID: 31884407]
MDA-MB-231 IC50
> 50 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
[PMID: 34022716]
MDA-MB-231 IC50
> 50 μM
Compound: Tamoxifen
Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 26972118]
MDA-MB-231 IC50
0.66 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
[PMID: 20451380]
MDA-MB-231 IC50
10 μM
Compound: TAM
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
[PMID: 24457094]
MDA-MB-231 IC50
10 μM
Compound: Tamoxifen
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
[PMID: 20605470]
MDA-MB-231 IC50
10.11 μM
Compound: TAM
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 34153643]
MDA-MB-231 IC50
11.2 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
[PMID: 31546197]
MDA-MB-231 IC50
11.4 μM
Compound: TAM
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
[PMID: 23287057]
MDA-MB-231 IC50
12.4 μM
Compound: Tamoxifen
Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
[PMID: 19836230]
MDA-MB-231 IC50
12.41 μM
Compound: Tamoxifen
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
[PMID: 23022281]
MDA-MB-231 IC50
13.9 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
[PMID: 27176944]
MDA-MB-231 IC50
14 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
[PMID: 24880230]
MDA-MB-231 IC50
14.5 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay
Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay
[PMID: 33421712]
MDA-MB-231 IC50
14.94 μM
Compound: 1
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 35276362]
MDA-MB-231 IC50
15.01 μM
Compound: Tamoxifen
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
[PMID: 33894490]
MDA-MB-231 GI50
15.1 μM
Compound: Tamoxifen
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay
[PMID: 28152429]
MDA-MB-231 IC50
17 μM
Compound: Tamoxifen
Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 23786452]
MDA-MB-231 IC50
18.48 μM
Compound: Tamoxifen
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay
[PMID: 37146520]
MDA-MB-231 IC50
18.9 μM
Compound: Tamoxifen
Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay
Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay
[PMID: 21871812]
MDA-MB-231 IC50
19 μM
Compound: Tamoxifen
Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay
Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay
[PMID: 12565971]
MDA-MB-231 IC50
20 μM
Compound: tamoxifene
Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay
[PMID: 19423356]
MDA-MB-231 IC50
24 μM
Compound: tamoxifen
Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay
Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay
[PMID: 19446930]
MDA-MB-231 IC50
25.1 μM
Compound: Tamoxifen
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
10.1007/s00044-012-0391-5
MDA-MB-231 IC50
27 μM
Compound: Tam
Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay
10.1039/C4MD00289J
MDA-MB-231 IC50
35.8 μM
Compound: Tamoxifen
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
[PMID: 33340662]
MDA-MB-231 IC50
38.97 μM
Compound: Tam
Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay
Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay
[PMID: 25222876]
MDA-MB-231 IC50
47.1 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
[PMID: 30360952]
MDA-MB-231 IC50
5.9 μM
Compound: Tamoxifen
Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
[PMID: 33373820]
MDA-MB-231 IC50
64.85 μM
Compound: 1, TAM
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
[PMID: 23860592]
MDA-MB-231 IC50
69.7 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
[PMID: 33139111]
MDA-MB-231 IC50
7 μM
Compound: Tamoxifen
Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 33373820]
MDA-MB-231 IC50
7.85 μg/mL
Compound: Tamoxifen
Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay
[PMID: 28442256]
MDA-MB-231 IC50
75 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
[PMID: 33234343]
MDA-MB-231 IC50
75 μM
Compound: Tamoxifen
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay
[PMID: 25164760]
MDA-MB-231 IC50
84.6 μM
Compound: Tamoxifen
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 25164760]
MDA-MB-231 IC50
9.86 μM
Compound: TAM
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
[PMID: 19740667]
MDA-MB-231 IC50
9.96 μM
Compound: Tamoxifen
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
[PMID: 29054359]
MDA-MB-435 GI50
3.16 μM
Compound: TAM
Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay
[PMID: 26896706]
MDA-MB-435S IC50
5.5 μM
Compound: Tamoxifen
Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay
Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay
[PMID: 26079090]
MDA-MB-468 IC50
14.99 μM
Compound: Tam
Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay
Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay
10.1039/C4MD00289J
MDA-MB-468 GI50
2.5 μM
Compound: TAM
Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay
[PMID: 26896706]
MEL-JUSO EC50
14.6 μM
Compound: TAM
Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
[PMID: 31099568]
M-HeLa IC50
28 μM
Compound: Tamoxifen
Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
[PMID: 31673312]
M-HeLa IC50
28 μM
Compound: Tamoxifen
Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method
Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method
[PMID: 31610378]
MIA PaCa-2 IC50
33.12 μM
Compound: Tam
Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay
Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay
[PMID: 25222876]
MOLT-4 GI50
2.5 μM
Compound: TAM
Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay
[PMID: 26896706]
MRC5 CC50
10 μM
Compound: Tamoxifen
Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay
Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay
[PMID: 33667089]
MRC5 IC50
10.9 μM
Compound: TAM
Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis
Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis
[PMID: 26922226]
MRC5 IC50
11.09 μM
Compound: Tamoxifen
Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay
Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay
[PMID: 30879839]
MRC5 CC50
11.09 μM
Compound: Tamoxifen
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay
[PMID: 30857749]
MRC5 IC50
11.09 μM
Compound: Tamoxifen
Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay
Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay
[PMID: 30692024]
MRC5 IC50
17.2 μM
Compound: Tamoxifen
Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
[PMID: 36242986]
MSTO-211H GI50
23.3 μM
Compound: 1
Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay
Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay
[PMID: 23735829]
NCI/ADR-RES IC50
11.13 μM
Compound: Tamoxifen
Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
[PMID: 23022281]
NCI-H460 GI50
4.48 μM
Compound: Tamoxifen
Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay
Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay
[PMID: 19733085]
NIH3T3 IC50
> 100 μM
Compound: Tam
Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay
Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay
[PMID: 25222876]
NIH3T3 IC50
11.4 μM
Compound: TAM
Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay
[PMID: 23287057]
NIH3T3 IC50
7.26 μM
Compound: 2
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
[PMID: 22749392]
OVCAR-5 GI50
32 μM
Compound: 1
Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay
[PMID: 27128175]
PC-3 IC50
> 1000 nM
Compound: 7
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
[PMID: 33479633]
PC-3 IC50
10 μM
Compound: TAM
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
[PMID: 23287057]
PC-3 IC50
15.8 μM
Compound: TAM
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 34153643]
PC-3 IC50
7 μM
Compound: Tamoxifen
Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay
[PMID: 24880230]
RAW264.7 CC50
11.1 μM
Compound: Tamoxifen
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay
[PMID: 31703818]
RAW264.7 IC50
18.5 μM
Compound: Tamoxifen
Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
[PMID: 36242986]
SH-SY5Y IC50
20 μM
Compound: Tamoxifen
Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis
Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis
[PMID: 27647375]
SK-BR-3 IC50
< 1000 μM
Compound: Tamoxifen
Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
[PMID: 36603398]
SK-BR-3 GI50
12.5 μM
Compound: Tamoxifen
Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay
[PMID: 28152429]
SK-BR-3 IC50
28.32 μM
Compound: Tamoxifen
Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay
Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay
[PMID: 33340662]
SK-BR-3 ED50
5 μg/mL
Compound: TAM
Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay
Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay
[PMID: 19425534]
SK-MEL-28 IC50
1.86 μg/mL
Compound: Tomoxifen
Cytotoxicity against human SK-MEL-28 cells by alamar blue assay
Cytotoxicity against human SK-MEL-28 cells by alamar blue assay
[PMID: 11720540]
SK-OV-3 GI50
10 μM
Compound: TAM
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
[PMID: 26896706]
SK-OV-3 GI50
6.4 μM
Compound: Tamoxifen
Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay
Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay
[PMID: 19733085]
SNB-75 GI50
5.01 μM
Compound: TAM
Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay
[PMID: 26896706]
T47D IC50
0.1 μM
Compound: Tamoxifen
Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay
Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay
[PMID: 19131248]
T47D IC50
1 μM
Compound: Tamoxifen
Growth inhibition of human estrogen-dependent T47D cells after 72 hrs
Growth inhibition of human estrogen-dependent T47D cells after 72 hrs
[PMID: 19131248]
T47D IC50
1.13 μM
Compound: Tamoxifen
Cytotoxicity against human T47D cells after 5 days
Cytotoxicity against human T47D cells after 5 days
[PMID: 23864928]
T47D GI50
1.99 μM
Compound: TAM
Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay
[PMID: 26896706]
T47D GI50
10.6 μM
Compound: Tamoxifen
Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay
[PMID: 28152429]
T47D IC50
12.1 μM
Compound: Tamoxifen
Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
10.1007/s00044-012-0391-5
T47D IC50
13 μM
Compound: TAM
Antiproliferative activity against human T47D cells after 48 hrs by MTT assay
Antiproliferative activity against human T47D cells after 48 hrs by MTT assay
[PMID: 23287057]
T47D IC50
14.2 μM
Compound: Tamoxifen
Antiproliferative activity against human T47D cells by MTT reduction assay
Antiproliferative activity against human T47D cells by MTT reduction assay
[PMID: 33421712]
T47D IC50
29.9 μM
Compound: Tam
Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay
Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay
10.1039/C4MD00289J
T47D IC50
34.42 μM
Compound: Tamoxifen
Antiproliferative activity against human T47D cells after 24 hrs by MTT assay
Antiproliferative activity against human T47D cells after 24 hrs by MTT assay
[PMID: 30731397]
THP-1 IC50
11.91 μM
Compound: Tamoxifen
Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
[PMID: 31884407]
UO-31 GI50
6.3 μM
Compound: TAM
Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay
[PMID: 26896706]
Vero IC50
15.9 μM
Compound: Tamoxifen
Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 23786452]
Vero IC50
36.2 μM
Compound: Tamoxifen
Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay
Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay
[PMID: 37146520]
Vero IC50
5.7 μM
Compound: Tamoxifen
Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay
[PMID: 26079090]
In Vitro

Tamoxifen (ICI 47699) shows strong inhibition of MCF-7 cells (EC50=1.41 μM) and to a lesser extent the T47D cells (EC50=2.5 μM) but does not affect the MDA-MB-231 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

1. Induction of gene knockout[8][9]
Background
Gene knockout model induced by tamoxifen uses Cre-Loxp mice. The Cre recombinase in these mice is driven by a tissue/cell-specific promoter, and the target gene is flanked by Loxp sites. The Cre recombinase is fused with the ligand-binding domain of the estrogen receptor to construct a Cre-ER fusion protein, and the recombination activity of Cre is induced by tamoxifen. In the absence of tamoxifen, the Cre-ER fusion protein binds to HSP90 and remains in the cytoplasm. After tamoxifen induction, the metabolite of tamoxifen, 4-OHT, binds to the Cre-ER protein, activates the Cre recombinase, and allows it to enter the nucleus. There, it recognizes the Loxp sites and mediates the knockout of the gene between two (in the same orientation) Loxp sites. (To avoid interference from endogenous estrogens, the ligand-binding domain of the estrogen receptor is modified, transforming Cre-ER into MerCreMer, Cre-ERT, or Cre-ERT2).
Specific Mmodeling Methods
Mice: Cx3cr1CreERT/+: Pdgfbfl/fl (Conditional knockout of Pdgfb in microglia)
Administration: i.p. • 5 consecutive days
Note
(1) Dissolution: Tamoxifen is poorly soluble in water and is generally dissolved in corn oil. It can be heated at 37°C or sonicated to assist dissolution, ensuring complete dissolution. Tamoxifen should be prepared in the dark and is recommended to be used freshly prepared. Corn oil is relatively viscous. When aspirating the solution, the needle can be left unplugged. After aspirating the solution, attach the needle and expel the air bubbles.
(2) Administration methods: Common methods include intraperitoneal injection, and it can also be administered by oral gavage or subcutaneous injection. When performing multiple intraperitoneal injections, the injection sites should be alternated.
(3) Dosage: The dosage is 50-120 mg/kg, with 3-5 intraperitoneal injections, usually for 5 consecutive days. The dosage for pregnant mice and aged mice (over 6 months old) should be appropriately reduced. Tamoxifen can affect fetal development and parturition. For pregnant mice, the induction time should preferably be selected in the late pregnancy stage, and progesterone should be injected simultaneously to reduce the probability of miscarriage.
(4) Mice: Mice at 4-6 weeks old may be more sensitive (it is more effective in young mice than in old mice).
(5) Potential toxicity: Prolonged high-level Cre activity can cause potential toxicity. In addition, if an important functional gene is knocked out, it may also lead to the death of mice. Therefore, close observation should be carried out within one or two weeks after induction. If the mice show abnormalities, the causes need to be analyzed in a timely manner and the experimental plan should be adjusted.
(6) Control: Control group mice should be injected with an equal amount of the corn oil solution of tamoxifen (using tamoxifen in a genetic background without Cre recombinase) to rule out the influence of tamoxifen itself.
(7) Detection window: The time window between tamoxifen administration and the start of the experiment should be large enough, at least 7 days, to ensure that the Cre recombinase enters the nucleus and functions.
(8) Separate caging: Animals treated with tamoxifen should be caged separately from untreated animals to avoid cross - contamination caused by behaviors such as animals licking the oily tamoxifen suspension, grooming their fur, or coprophagy.
Modeling Indicators
Verify the reduced expression/knockout of the target gene at the RNA or protein level through molecular biology and genetic methods (such as Western blot, PCR, and sequencing, etc.).
Correlated Product(s): 4-Hydroxytamoxifen (HY-16950)
Opposite Product(s): /
2. Induction of liver injury[10]
Background
Tamoxifen reduces the hexose monophosphate shunt, thereby increasing the incidence of oxidative stress in rat hepatocytes, leading to liver injury.
Specific Mmodeling Methods
Albino rat &bull ; female &bull ; period: 7 days
Administration: 45 mg/kg •ip • once daily for 7 days
Note
(1) The rats were kept in a standard laboratory environment, which was a 12-hour light/12-hour dark cycle with the temperature maintained at 25 ± 2°C. They had free access to food and water.
(2) At the end of the experiment, the animals were euthanized by cervical dislocation under mild ether anesthesia. The blood samples were collected in heparinized centrifuge tubes and centrifuged to obtain serum. The abdomen was opened, and the liver was immediately dissected and removed. It was washed with ice-cold isotonic saline and blotted between two filter papers. The liver was wrapped in aluminum foil and stored at -80°C. A 10% (w/v) liver homogenate was prepared in ice-cold 0.1 M potassium phosphate buffer (pH 7.5) using an ultrasonicator.
Modeling Indicators
Molecular Changes: The activities of antioxidant enzymes, including glutathione S-transferase, glutathione peroxidase, and catalase, were significantly ↓, while the content of reduced glutathione also showed a ↓ trend. Concurrently, the levels of thiobarbituric acid reactive substances (TBARS) and liver transaminases, including serum glutamic-pyruvic transaminase (sGPT) and serum glutamic-oxaloacetic transaminase (sGOT), were significantly ↑.
Correlated Product(s): /
Opposite Product(s): /

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Aldh1l1-cre/ERT2 x Ai95 mice[3]
Dosage: 75 mg/kg
Administration: Injected for 5 days at 6 weeks of age
Result: Resulted in the excision of the floxed exon and a gene knockout.
Klinische Studie
Molekulargewicht

371.51

Formel

C26H29NO

CAS. Nr.
Appearance

Solid

Color

White to off-white

SMILES

CC/C(C1=CC=CC=C1)=C(C2=CC=CC=C2)/C3=CC=C(C=C3)OCCN(C)C

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit
In Vitro: 

Ethanol : 50 mg/mL (134.59 mM; Need ultrasonic)

DMSO : 25 mg/mL (67.29 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.6917 mL 13.4586 mL 26.9172 mL
5 mM 0.5383 mL 2.6917 mL 5.3834 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (5.60 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.08 mg/mL (5.60 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  Corn Oil

    Solubility: 40 mg/mL (107.67 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation
Verweise

Sie könnten auch an folgenden Produkten interessiert sein:



Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.
B5965-5g
 5g 
HY-10087-10mg
 10mg